Pediatric invasive fungal rhinosinusitis: An investigation of 17 patients
- PMID: 28688551
- DOI: 10.1016/j.ijporl.2017.05.015
Pediatric invasive fungal rhinosinusitis: An investigation of 17 patients
Abstract
Purpose: To investigate outcomes of pediatric patients at a single institution with invasive fungal rhinosinusitis (IFRS) and to determine variables that impact overall survival.
Methods: All pediatric patients at a large tertiary children's hospital diagnosed with IFRS confirmed by surgical pathology from 2009 to 2015 were retrospectively reviewed. Demographics, underlying diseases, symptoms, antifungal therapy, absolute neutrophil count (ANC), surgical management,and outcomes were analyzed.
Results: Seventeen patients were identified with IFRS with an average age of 8.7 years and 53% male. Hematologic malignancy was the most common (n = 13) underlying disease. The most common presenting symptoms were fever (82%) and congestion (41%). 15 patients had severe neutropenia (Absolute Neutrophil Count (ANC) < 500) within 2 weeks prior to diagnosis. The average ANC at time of diagnosis was 1420 cells/uL. 16 patients were treated with serial nasal endoscopy and debridement, while 1 patient was treated with an open approach. 16 received combination antifungals while 1 was treated with amphotericin monotherapy. The most common genus cultured was Fusarium (n = 6). The average number of surgical interventions was 3.4, with the average interval between interventions 6.2 days. 13 of 17 (76%) were cleared of IFRS. Overall survival at 6 months was 41%.
Conclusion: Pediatric IFRS is a life-threatening disease that requires a coordinated surgical and medical approach. Despite a relatively high local control rate, overall mortality remains disappointingly high, reflecting the disease's underlying pathogenesis - lack of host defense and risk of disseminated fungal infection. Further investigation is necessary to reveal optimal management with regards to antifungal therapy, surgery, and utility of labs.
Keywords: Fungal; IFRS; Invasive; Pediatric; Rhinosinusitis; Sinusitis.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Factors associated with all-cause mortality in pediatric invasive fungal rhinosinusitis.Int J Pediatr Otorhinolaryngol. 2020 Feb;129:109734. doi: 10.1016/j.ijporl.2019.109734. Epub 2019 Oct 30. Int J Pediatr Otorhinolaryngol. 2020. PMID: 31683190
-
Prognosis of acute invasive fungal rhinosinusitis related to underlying disease.Int J Infect Dis. 2011 Dec;15(12):e841-4. doi: 10.1016/j.ijid.2011.08.005. Epub 2011 Oct 2. Int J Infect Dis. 2011. PMID: 21963345
-
Fungal rhinosinusitis: a retrospective analysis of clinicopathologic features and treatment outcomes at Ramathibodi Hospital.Southeast Asian J Trop Med Public Health. 2010 Mar;41(2):442-9. Southeast Asian J Trop Med Public Health. 2010. PMID: 20578529
-
Treatment outcomes in acute invasive fungal rhinosinusitis.Curr Opin Otolaryngol Head Neck Surg. 2014 Jun;22(3):242-8. doi: 10.1097/MOO.0000000000000048. Curr Opin Otolaryngol Head Neck Surg. 2014. PMID: 24756031 Review.
-
Invasive fungal sinusitis in patients undergoing bone marrow transplantation.Bone Marrow Transplant. 1993 Sep;12(3):203-8. Bone Marrow Transplant. 1993. PMID: 8241977 Review.
Cited by
-
Invasive Fusarium rhinosinusitis in COVID-19 patients: report of three cases with successful management.Front Cell Infect Microbiol. 2023 Sep 14;13:1247491. doi: 10.3389/fcimb.2023.1247491. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37780844 Free PMC article.
-
Acute invasive fungal rhinosinusitis in pediatric patients with oncohematological diseases.Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):32-39. doi: 10.1016/j.htct.2020.08.016. Epub 2020 Nov 9. Hematol Transfus Cell Ther. 2022. PMID: 33288493 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical